Quark Becomes First to Test Systemic RNAi Drug in Humans, Sees Data Driving IPO | GenomeWeb
This article has been updated from a previous version to clarify Quark's licensing agreement for the structure of AKIi-5 with Silence Therapeutics.
 
Quark Pharmaceuticals this week announced that it has begun dosing patients in a phase I trial of AKLi-5, an siRNA-based treatment for acute renal failure, marking what the company said is the first time a systemic RNAi-based drug has been administered to humans (see sidebar below).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.